Bittner Sebastian, Knoll Gertrud, Ehrenschwender Martin
Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, Germany.
FEBS Lett. 2017 Apr;591(8):1187-1195. doi: 10.1002/1873-3468.12632. Epub 2017 Apr 10.
Exploiting regulatory T cells (Tregs) to control aberrant immune reactions is a promising therapeutic approach, but is hampered by their relative paucity. In mice, activation of death receptor 3 (DR3), a member of the TNF-receptor superfamily (TNFRSF), increases Treg frequency and efficiently controls exuberant immune activation. For human Tregs, neither DR3 expression nor potential functions have been described. Here, we show that human Tregs express DR3 and demonstrate DR3-mediated activation of p38, ERK, and NFκB. DR3 stimulation enhances Treg expansion ex vivo while retaining their suppressive capacity. In summary, our results establish a functional role for DR3 signaling in human Tregs and could potentially help to tailor Treg-based therapies.
利用调节性T细胞(Tregs)来控制异常免疫反应是一种很有前景的治疗方法,但由于其数量相对稀少而受到阻碍。在小鼠中,肿瘤坏死因子受体超家族(TNFRSF)成员死亡受体3(DR3)的激活会增加Treg频率,并有效控制过度的免疫激活。对于人类Tregs,尚未描述DR3的表达及其潜在功能。在此,我们表明人类Tregs表达DR3,并证明DR3介导p38、ERK和NFκB的激活。DR3刺激可增强体外Treg的扩增,同时保留其抑制能力。总之,我们的结果确立了DR3信号在人类Tregs中的功能作用,并可能有助于定制基于Treg疗法。